GlassScriptPhysician profile
Elber Camacho
NPI 1598761710
$15,370.95
in general payments reported to CMS, 2019-2025
61 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,310 · 2020: $6,399 · 2021: $427 · 2022: $1,138 · 2023: $1,313 · 2024: $1,268 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,097.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,287.48 | 2019-2025 | Enhertu, Lynparza, Datroway |
| Kite Pharma, INC. | $1,594.84 | 2020-2024 | Yescarta |
| Epizyme, INC. | $1,500.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $707.02 | 2019-2023 | Opdivo |
| Merck Sharp & Dohme LLC | $499.25 | 2019-2025 | Keytruda Qlex, Keytruda, Welireg |
| Regeneron Healthcare Solutions, INC. | $457.82 | 2024-2025 | Libtayo |
| Genentech USA, INC. | $434.38 | 2019-2022 | |
| Janssen Biotech, INC. | $422.82 | 2019-2025 | Imbruvica, Darzalex, Talvey |
| Amgen INC. | $370.13 | 2019-2022 | |
| Glaxosmithkline, LLC. | $349.71 | 2022-2025 | Jemperli |
| Incyte Corporation | $292.90 | 2019-2025 | Monjuvi, Jakafi |
| Pfizer INC. | $265.47 | 2019-2025 | |
| Novocure INC. | $237.92 | 2022-2024 | Optune |
| Genzyme Corporation | $237.14 | 2019-2023 | |
| Karyopharm Therapeutics INC. | $227.43 | 2020-2025 | Xpovio |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elber Camacho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.